Syndax Pharmaceuticals' FDA decision on leukemia drug revumenib delayed by 3 months to Dec 26.
Syndax Pharmaceuticals' FDA decision on its leukemia drug revumenib, initially set for Sept. 26, has been delayed by three months, pushing the decision date to December 26. The FDA requested additional time to review supplemental information submitted by Syndax, which led to the extension of the PDUFA action date for the New Drug Application. The delay has caused a drop in Syndax's stock value.
July 29, 2024
7 Articles